1.Transvaginal Drainage of Pelvic Collections: a 5-year Retrospective Review in a Tertiary Gynaecology Centre.
Lun Yin CHONG ; Han Wei TOH ; Chiou Li ONG
Annals of the Academy of Medicine, Singapore 2016;45(1):31-34
Abscess
;
surgery
;
Adult
;
Aged
;
Aged, 80 and over
;
Cysts
;
surgery
;
Drainage
;
methods
;
Endometriosis
;
surgery
;
Fallopian Tube Diseases
;
surgery
;
Female
;
Humans
;
Middle Aged
;
Ovarian Cysts
;
surgery
;
Pelvis
;
surgery
;
Retrospective Studies
;
Surgery, Computer-Assisted
;
Tertiary Care Centers
;
Treatment Outcome
;
Ultrasonography
;
Ultrasonography, Interventional
;
methods
;
Vagina
;
Young Adult
2.Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer.
Jia Wei ANG ; Min-Han TAN ; Miah Hiang TAY ; Chee Keong TOH ; Quan Sing NG ; Ravindran KANESVARAN
Annals of the Academy of Medicine, Singapore 2017;46(5):195-201
INTRODUCTIONHigh levels of toxicities have been observed when docetaxel is administered at the standard dose of 75 mg/mevery 3 weeks (Q3W) in the real-world treatment of Asian patients with metastatic castrate-resistant prostate cancer (CRPC). This study aimed to evaluate the efficacy and tolerability of 2 attenuated regimens more widely used in an Asian setting to minimise toxicity - 60 mg/mQ3W and weekly docetaxel (20 mg/mto 35 mg/m).
MATERIALS AND METHODSMedical records of 89 CRPC patients between December 2003 and April 2013 were reviewed. Pairwise statistical analysis was performed, comparing efficacy and safety outcomes of 75 mg/mQ3W and weekly docetaxel with 60 mg/mQ3W. Treatment endpoints used were prostate-specific antigen (PSA) response (decrease of ≥50% from baseline), pain improvement after cycle 2, overall survival, time to disease progression and radiological response.
RESULTSPatients who received docetaxel at 75 mg/mQ3W were younger than those who received 60 mg/mQ3W (62 years and 66 years, respectively;= 0.0489). Both groups had similar response rates. Compared with patients on 60 mg/mQ3W, more patients on weekly regimens were symptomatic at baseline (63.2% and 87.5%, respectively;= 0.0173). Longer overall survival was observed in the 60 mg/mQ3W arm than the weekly docetaxel arm (16.9 months and 10.6 months, respectively;= 0.0131), though other measures of response did not differ significantly.
CONCLUSIONOur data supports the use of 60 mg/mQ3W docetaxel which has similar efficacy and an acceptable toxicity profile compared to the standard 75 mg/mQ3W regimen. Weekly docetaxel has significant palliative benefits among symptomatic patients despite lower overall survival.